



## Product Information


**Product ID** Q8139  
**CAS No.** 950769-58-1  
**Chemical Name** 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea  
**Synonym** AC220, AC-220

**Formula** C<sub>29</sub>H<sub>32</sub>N<sub>6</sub>O<sub>4</sub>S  
**Formula Wt.** 560.67  
**Melting Point**  
**Purity** ≥98%  
**Solubility**

**Store Temp** -20°C  
**Ship Temp** Ambient

**Description** Quizartinib is an anticancer chemotherapeutic compound that inhibits FMS-like tyrosine kinase 3 (FLT3), c-Kit, and PDGFR. Quizartinib is clinically used to treat acute myelogenous leukemia. In cellular models, quizartinib induces apoptosis and inhibits proliferation. This compound also inhibits ATP-binding cassette ABCG2, also known as breast cancer resistance protein.

Quizartinib is supplied as a crystalline solid. Quizartinib is soluble in DMSO to 33 mg/mL, in water to <0.3 mg/mL, and in ethanol to <0.5 mg/mL. If Quizartinib needs to be stored long term, we recommend storing the solid Quizartinib and not storing the Quizartinib in solution due to potential loss of stability.



## Pricing and Availability

**Bulk quantities available upon request**

Product ID	Size	List Price
Q8139	5 mg	\$204.30
Q8139	10 mg	\$357.30
Q8139	25 mg	\$714.70

**References** Ostronoff F, Estey E. The role of quizartinib in the treatment of acute myeloid leukemia. *Expert Opin Investig Drugs*. 2013 Sep 26. [Epub ahead of print]. PMID: 24070241.

Bhullar J, Natarajan K, Shukla S, et al. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. *PLoS One*. 2013;8(8):e71266. PMID: 23967177.

Kampa-Schittenhelm KM, Heinrich MC, Akmut F, et al. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. *Mol Cancer*. 2013 Mar 7;12:19. PMID: 23497317.

Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). *Blood*. 2009 Oct 1;114(14):2984-92. PMID: 19654408.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.